These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 38981723)

  • 1. Decriminalisation and smart regulation of psychoactive substances: a modern alternative to prohibition.
    Mravčík V
    Cas Lek Cesk; 2023; 162(6):231-237. PubMed ID: 38981723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding the development of a regulated market approach to new psychoactive substances (NPS) in New Zealand using Punctuated Equilibrium Theory.
    Rychert M; Wilkins C
    Addiction; 2018 Nov; 113(11):2132-2139. PubMed ID: 29744945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Weighing the benefits and harms of psychotropic and analgesic substances - A perspective of German addiction medicine experts].
    Bonnet U; Specka M; Soyka M; Alberti T; Bender S; Hilger J; Hillemacher T; Kuhlmann T; Kuhn J; Lüdecke C; Reimer J; Schneider U; Schroeder W; Stuppe M; Wiesbeck G; Wodarz N; Scherbaum N
    Fortschr Neurol Psychiatr; 2022 Jan; 90(1-02):19-29. PubMed ID: 33634461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can new psychoactive substances be regulated effectively? An assessment of the British Psychoactive Substances Bill.
    Reuter P; Pardo B
    Addiction; 2017 Jan; 112(1):25-31. PubMed ID: 27220685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New psychoactive substances: Are there any good options for regulating new psychoactive substances?
    Reuter P; Pardo B
    Int J Drug Policy; 2017 Feb; 40():117-122. PubMed ID: 27889115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Legal high industry business and lobbying strategies under a legal market for new psychoactive substances (NPS, 'legal highs') in New Zealand.
    Rychert M; Wilkins C
    Int J Drug Policy; 2016 Nov; 37():90-97. PubMed ID: 27639994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Worldwide legislative challenges related to psychoactive drugs.
    Negrei C; Galateanu B; Stan M; Balalau C; Dumitru MLB; Ozcagli E; Fenga C; Kovatsi L; Fragou D; Tsatsakis A
    Daru; 2017 Jun; 25(1):14. PubMed ID: 28578694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Issues with monitoring the safety of psychoactive products under a legal regulated market for new psychoactive substances ('legal highs') in New Zealand.
    Rychert M; Wilkins C; Witten K
    Drug Alcohol Rev; 2017 Sep; 36(5):589-596. PubMed ID: 28229493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Psychoactive Substances and receding COVID-19 pandemic: really going back to "normal"?
    Napoletano S; Basile G; Lo Faro AF; Negro F
    Acta Biomed; 2022 May; 93(2):e2022186. PubMed ID: 35545997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A critical analysis of the implementation of a legal regulated market for new psychoactive substances ("legal highs") in New Zealand.
    Rychert M; Wilkins C
    Int J Drug Policy; 2018 May; 55():88-94. PubMed ID: 29524738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What products are considered psychoactive under New Zealand's legal market for new psychoactive substances (NPS, 'legal highs')? Implications for law enforcement and penalties.
    Rychert M; Wilkins C
    Drug Test Anal; 2016 Aug; 8(8):768-78. PubMed ID: 26857892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The challenge of a ban on animal testing for the development of a regulated legal market for new psychoactive substances (NPS) ('legal highs') in New Zealand: Issues and options for resolution.
    Rychert M; Wilkins C
    Int J Drug Policy; 2015 Dec; 26(12):1273-8. PubMed ID: 26364077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing options for cannabis law reform: A Multi-Criteria Decision Analysis (MCDA) with stakeholders in New Zealand.
    Wilkins C; Rychert M; Queirolo R; Lenton SR; Kilmer B; Fischer B; Decorte T; Hansen P; Ombler F
    Int J Drug Policy; 2022 Jul; 105():103712. PubMed ID: 35537275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Taking the cat-and-mouse game to the next level: different perspectives on the introduction of the German New Psychoactive Substances Act.
    Kühnl R; Aydin D; Horn S; Olderbak S; Verthein U; Kraus L
    Harm Reduct J; 2022 Nov; 19(1):122. PubMed ID: 36329471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An ethical analysis of UK drug policy as an example of a criminal justice approach to drugs: a commentary on the short film Putting UK Drug Policy into Focus.
    Holland A
    Harm Reduct J; 2020 Dec; 17(1):97. PubMed ID: 33298088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multi criteria decision analysis (MCDA) for evaluating and appraising government policy responses to non medical heroin use.
    Rolles S; Schlag AK; Measham F; Phillips L; Nutt D; Bergsvik D; Rogeberg O
    Int J Drug Policy; 2021 May; 91():103180. PubMed ID: 33640213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The new psychoactive substances regime in New Zealand: a different approach to regulation.
    Wilkins C; Sheridan J; Adams P; Russell B; Ram S; Newcombe D
    J Psychopharmacol; 2013 Jul; 27(7):584-9. PubMed ID: 23739179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of the COVID-19 pandemic on the use of the performance-enhancing drugs.
    Negro F; Di Trana A; Marinelli S
    Acta Biomed; 2022 Jan; 92(6):e2021401. PubMed ID: 35075058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Minderoo-Monaco Commission on Plastics and Human Health.
    Landrigan PJ; Raps H; Cropper M; Bald C; Brunner M; Canonizado EM; Charles D; Chiles TC; Donohue MJ; Enck J; Fenichel P; Fleming LE; Ferrier-Pages C; Fordham R; Gozt A; Griffin C; Hahn ME; Haryanto B; Hixson R; Ianelli H; James BD; Kumar P; Laborde A; Law KL; Martin K; Mu J; Mulders Y; Mustapha A; Niu J; Pahl S; Park Y; Pedrotti ML; Pitt JA; Ruchirawat M; Seewoo BJ; Spring M; Stegeman JJ; Suk W; Symeonides C; Takada H; Thompson RC; Vicini A; Wang Z; Whitman E; Wirth D; Wolff M; Yousuf AK; Dunlop S
    Ann Glob Health; 2023; 89(1):23. PubMed ID: 36969097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A critical first assessment of the new pre-market approval regime for new psychoactive substances (NPS) in New Zealand.
    Wilkins C
    Addiction; 2014 Oct; 109(10):1580-6. PubMed ID: 24529166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.